Literature DB >> 20495978

Percutaneous isolated liver perfusion with occlusion balloons and a catheter-based stent-graft-like perfusion device: an experimental study in a porcine model.

Geert Maleux1, Diethard Monbaliu, Chris Verslype, Christophe Casteleyn, Marc Van De Velde, Pieter Cornillie, Yvonne Hoogeveen, Eric Van Cutsem.   

Abstract

OBJECTIVE: To evaluate the feasibility and safety of a novel percutaneous isolated liver perfusion (PILP) system in a porcine model.
METHODS: The PILP catheter set, consisting of a portal vein and hepatic artery occlusion balloon and an hourglass-shaped vena cava stent-graft, was tested in six Dutch Landrace pigs. A veno-venous bypass between the distal portal vein and the right femoral vein, and isolated perfusion between the proximal portal vein and the hepatic veins were also created. Leak rate was determined using radioactivity measurement in the systemic circulation. Perfusion was then performed without (n = 2) or with cytotoxic drugs (n = 4). At the end of the procedure, all devices were retrieved and angiographic evaluation was performed of the involved vessel segments.
RESULTS: In all pigs it was possible to insert, accurately position and retrieve all components of the PILP catheter set without angiographic signs of vessel-wall damage. Leakage rates to the systemic circulation were less than 7% over the course of the perfusion.
CONCLUSION: In a porcine model, the PILP system can be safely and accurately positioned, and showed successful vascular isolation of the liver, with a leak rate to the systemic circulation of less than 7%.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20495978     DOI: 10.1007/s00330-010-1816-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  25 in total

Review 1.  Recent trends and future perspectives in isolated hepatic perfusion in the treatment of liver tumors.

Authors:  J Rothbarth; R A E M Tollenaar; C J H van de Velde
Journal:  Expert Rev Anticancer Ther       Date:  2006-04       Impact factor: 4.512

2.  Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs.

Authors:  M G van Ijken; E A de Bruijn; G de Boeck; T L ten Hagen; J R van der Sijp; A M Eggermont
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

3.  Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure.

Authors:  A M Eggermont; M G van IJken; B van Etten; J R van der Sijp; T L ten Hagen; T Wiggers; M Oudkerk; G de Boeck; E A de Bruijn
Journal:  Hepatogastroenterology       Date:  2000 May-Jun

4.  Isolated liver perfusion using percutaneous methods: an experimental study in the pig.

Authors:  J Harnek; W Cwikiel; L Bergqvist; B Persson; H Stridbeck
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Nov-Dec       Impact factor: 2.740

5.  Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies.

Authors:  S K Libutti; D L Barlett; D L Fraker; H R Alexander
Journal:  J Am Coll Surg       Date:  2000-11       Impact factor: 6.113

6.  Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study.

Authors:  Eric Savier; Daniel Azoulay; Emmanuel Huguet; François Lokiec; Marian Gil-Delgado; Henri Bismuth
Journal:  Arch Surg       Date:  2003-03

7.  Relevant radiological anatomy of the pig as a training model in interventional radiology.

Authors:  R F Dondelinger; M P Ghysels; D Brisbois; E Donkers; F R Snaps; J Saunders; J Devière
Journal:  Eur Radiol       Date:  1998       Impact factor: 5.315

8.  Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver.

Authors:  Saidja L Noter; Joost Rothbarth; Milan E J Pijl; Jan E E Keunen; Henk H Hartgrink; Fred G J Tijl; Peter J K Kuppen; Cornelis J H van de Velde; Rob A E M Tollenaar
Journal:  Melanoma Res       Date:  2004-02       Impact factor: 3.599

9.  Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center.

Authors:  H Richard Alexander; David L Bartlett; Steven K Libutti; James F Pingpank; Douglas L Fraker; Richard Royal; Seth M Steinberg; Cynthia B Helsabeck; Tatiana H Beresneva
Journal:  Ann Surg Oncol       Date:  2009-05-12       Impact factor: 5.344

10.  Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients.

Authors:  L B J van Iersel; H Gelderblom; A L Vahrmeijer; E L van Persijn van Meerten; F G J Tijl; H Putter; H H Hartgrink; P J K Kuppen; J W R Nortier; R A E M Tollenaar; C J H van de Velde
Journal:  Ann Oncol       Date:  2008-02-27       Impact factor: 32.976

View more
  1 in total

1.  Flushing out antibodies to make AAV gene therapy available to more patients.

Authors:  Steven E Raper; James M Wilson; Frederick A Nunes
Journal:  Mol Ther       Date:  2013-02       Impact factor: 11.454

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.